Aegerion aims for $68m to fund Juxtapid launch
This article was originally published in Scrip
Executive Summary
Aegerion Therapeutics is aiming to raise net proceeds of $67.9 million in a public offering that it expects to close this week. The firm is seeking cash to fund the commercial launch of Juxtapid (lomitapide), its first product, which received FDA approval as a treatment for patients with the rare genetic disease homozygous familial hypercholesterolemia (HoFH) last month.